JAK2 and cancer: Interestingly, a combination consisting of trastuzumab and ruxolitinib – a JAK1/JAK2 inhibitor – demonstrated a synergistic cancer inhibition in mouse xenografts of HER2 transformed BC cell lines (Rodriguez-Barrueco et al., 2015).